| Date | Title | Description |
| 06.09.2024 | Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 | Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunothe... |
| 13.08.2024 | Immatics Announces Second Quarter 2024 Financial Results and Business Update | Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain... |
| 31.07.2024 | Immatics Appoints Alise Reicin to Board of Directors | Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapie... |
| 21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| 17.11.2023 | Is This European Biotech Startup Revolutionizing Immunotherapy Cancer Treatments? | Key Takeaways:
Company: immatics biotechnologies
Industry: Biotechnology, Medical, Therapeutics
Location: Tübingen, Baden-Wurttemberg, Germany
Focus: Development of immunotherapeutic substances for cancer therapy
Pushing the boundaries of ... |
| 11.09.2023 | Moderna and Immatics jointly develop innovative oncology therapeutics | Moderna, Inc. and Immatics N.V. enter into a multi-billion dollar strategic research and development collaboration to jointly develop novel and transformative therapies for cancer patients with high unmet medical needs. Both biotechnology c... |
| 24.07.2023 | Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb | - |
| 17.11.2022 | Immatics Announces Third Quarter 2022 Financial Results and Business Update | Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and Phase 1b; confirmed responses seen across di... |
| 17.11.2022 | Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung | Klinisches Daten-Update zu ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigt hohe bestätigte objektive Ansprechrate (confirmed objective response rate, cORR) von 50 % (6/12) bei Patienten der Phase 1a und Phase 1b, die... |
| 10.10.2022 | Immatics Announces $110 Million Underwritten Offering of Ordinary Shares | Houston, Texas and Tuebingen, Germany, October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced t... |
| 10.10.2022 | Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME | Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients wi... |
| 10.09.2022 | Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 | TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME
In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity in vivo and reduced T cell engager-a... |
| 23.08.2022 | Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME | IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against PRAME
Preclinical data with IMA203CD8 showed enhanced potency and prolonged anti-... |
| 09.08.2022 | Immatics Announces Second Quarter 2022 Financial Results and Business Update | ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A), IMA203/nivolumab checkpoint inhibitor combination (Cohort B) an... |
| 07.06.2022 | Immatics und Editas Medicine schließen strategische Forschungskollaboration zur Kombination von gamma-delta T-Zelltherapien mit Gene-Editing-Technologien für die Behandlung von Krebs ab | Tübingen, Deutschland, Houston, Texas und Cambridge, Massachusetts, 7. Juni 2022 – Immatics N.V. (Nasdaq: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-basierten Immuntherapien für die Behandlun... |
| 02.06.2022 | Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs | New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo® with Bristol Myers Squibb’s technologies and oncology drug development expertiseImm... |
| 02.06.2022 | Immatics Announces First Quarter 2022 Financial Results and Business Update | ACTengine® IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with 2nd-generation IMA203CD8 granted
Phase ... |
| 18.05.2022 | Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors | The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint inhibitor, in patients with multiple solid... |
| 10.05.2022 | Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors | Patient enrollment for IMA401 Phase 1 trial started at first clinical site in GermanyThe study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors TCER® IMA... |
| 23.03.2022 | Immatics Announces Full Year 2021 Financial Results and Corporate Update | IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation
Multiple IMA203 Phase 1b expansion cohorts being initiated in Q2 2022 incl... |
| 14.12.2021 | Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401 | Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US
Immatics to receive upfront payment of $150 ... |
| 14.12.2021 | Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401 | Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US
Immatics to receive upfront payment of $150 ... |
| 16.11.2021 | Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update | Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation phase
Immatics to initiate three expansion cohorts for IMA203 targeting... |
| 16.11.2021 | Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update | Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation phase
Immatics to initiate three expansion cohorts for IMA203 targeting... |
| 09.11.2021 | Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME | Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) ob... |
| 01.11.2021 | Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting | Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today annou... |
| 30.03.2021 | IMMATICS N.V.
Press Release: Immatics Announces Full Year 2020 Financial Results and Corporate Update | -- Phase 1a data update from clinical ACTengine(R) programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients -- Enrollment across clinical ACTengine(R) IMA200 trial serie... |
| 18.03.2021 | Immatics N : ACTengine Combined Data Readout presentation March2021 | ACTengine® IMA200 Clinical Trial Series Phase 1a Data Update
Cedrik Britten, Chief Medical Officer Harpreet Singh, Chief Executive Officer March 17, 2021
© Immatics. Not for further reproduction or distribution.
Forward-Looking Statements
T... |
| 17.03.2021 | Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs | Company to host conference call on Wednesday, March 17 at 8:30 am EST
·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation
·Tumor shrinkage observed in 8 out of 10 patients ... |
| 28.08.2019 | Immatics and Celgene enter strategic collaboration to develop novel adoptive cell therapies | Immatics and Celgene have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. Immatics may develop T-Cell Receptor Engineered T-cell Therapy (TCR-T) programs again... |
| 28.08.2019 | Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership | The deal includes a $75 million investment in the company by Celgene. Immatics would develop TCRs against solid tumor cancers using its in-house technology. It would be responsible for their development and validation through the lead candi... |
| 08.07.2019 | Immatics appoints Harpreet Singh as Chief Executive Officer | Immatics today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO). Harpreet Singh has most recently been President and CEO of Immatics US and Chief Scientific Officer (CSO) of the Company, having co... |
| 27.02.2019 | Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers | Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers. IMA101 is a... |
| 17.01.2018 | Immatics appoints Thomas Ulmer as Chief Financial Officer | Immatics today announced the appointment of Thomas Ulmer as Chief Financial Officer, effective April 1st, 2018. Thomas Ulmer joins Immatics from the Merck Group, where he is currently Chief Financial Officer of the Allergopharma Business Un... |
| 05.10.2017 | Term Sheet — Thursday, October 5 | LIFE SCIENCES $$$
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
There’s been plenty of activity in the cancer immunotherapy space recently. In August, Gilead Sciences bought Kite Pharma... |
| 04.10.2017 | Immatics Closes $58m Series E Financing Round | Immatics, a Tuebingen, Germany-based cancer immunotherapy company, closed a $58m Series E financing round.
Backers included dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and Amgen.
The company intends to use the funds to c... |
| 04.10.2017 | Immatics Raises $58M | Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.
The Series E funding was supported by existing investors including dievini Hopp Biotech holding... |
| 04.10.2017 | Immatics Raises $58M | Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.
The Series E funding was supported by existing investors including dievini Hopp Biotech holding... |
| 04.10.2017 | Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies | - |
| 04.10.2017 | Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies | Immatics today announced the completion of its Series E financing, raising $58 million. |
| 04.10.2017 | Amgen helps Immatics to $58M round to fund cancer trials | Immatics has raised $58 million (€49 million) to push its cancer immunotherapies deeper into the clinic. The German T-cell specialist turned to its existing investors and new partner Amgen to put together the round, which brings its amount ... |
| 04.10.2017 | Amgen helps Immatics to $58M round to fund cancer trials | Immatics has raised $58 million (€49 million) to push its cancer immunotherapies deeper into the clinic. The German T-cell specialist turned to its existing investors and new partner Amgen to put together the round, which brings its amount ... |
| 28.09.2017 | Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers | Immatics today announced that it has initiated enrollment of patients into a Phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program. |
| 21.08.2017 | Immatics initiates personalized adoptive cellular therapy in patients with relapsed and/or refractory solid cancers using its pioneering target warehouse | Immatics today announced that it has initiated enrolment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA101 phase I trial is the first industry-sponsored... |
| 09.01.2017 | immatics and Amgen sign $1B deal | Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies |
| 16.07.2014 | immatics biotechnologies Receives €22M; Completes €34M Series D Financing | immatics biotechnologies GmbH, a Tuebingen and Martinsried (Munich), Germany-based clinical-stage biopharmaceutical company, received €22m to complete a Series D financing round.
The company, which received €12m in October 2013 as an initia... |
| 16.07.2014 | Cancer vaccine maker immatics adds nearly $30M in Series D | Immatics CEO Paul Higham
After scooping up an initial €12 million ($16.2 million) in October and a partnering pact with Roche ($RHHBY) in November, Germany's immatics has received an additional €22 million ($29.8 million) to wrap up a Serie... |
| 21.11.2013 | With $4.2M raise, Immunovaccine says it’s set through 2014, has 3 cancer vaccine trials in the works | “Normal vaccines get cleared from site of injection within hours or days. You have to repeatedly vaccinate, and even then you might not generate a strong immune response,” Chief Operating Officer Marc Mansour explained during a recent inter... |
| 17.10.2013 | Immatics Closes 34M EURO Series D Round |
MUNICH/TUEBINGEN, GERMANY, Immatics Biotechnologies has closed a 34 million euro Series D financing round to continue development of cancer vaccines.
>> Click here for more funding data on Immatics Biotechnologies
>> To expo... |
| 15.10.2013 | immatics biotechnologies Closes €34M Series D Round | immatics biotechnologies GmbH, a German clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, raised the €12m first tranche of a €34m Series D financing round.
Backers inc... |
| 21.09.2010 | immatics biotechnologies Raises €53.8M in Series C Financing Round | immatics biotechnologies GmbH, a Tuebingen and Munich, Germany-based biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, has raised €53.8m in a Series C financing round.
The round was supported... |
| - | With $4.2M raise, Immunovaccine says it’s set through 2014, has 3 cancer vaccine trials in the works | Analysts say there’s a multibillion-dollar market up for the taking for companies who figure out how to turn on the immune system to fight tumor cells and delay the progression of cancer. Canadian company Immunovaccine wants a piece of that... |
| - | Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership | A large biotech company is pouring tens of millions of dollars into a German firm under a partnership to develop cell therapies in oncology.
Immatics Biotechnologies, based near Munich, said Wednesday that it had entered the partnership wit... |
